DDX17 Activators represent a chemical class specifically designed to modulate the expression or activity of the DDX17 protein, a member of the DEAD box protein family. The DEAD box proteins are crucial in RNA metabolism, playing pivotal roles in RNA splicing, ribosome assembly, and translation initiation. DDX17, in particular, functions as an ATP-dependent RNA helicase, unwinding RNA secondary structures necessary for efficient RNA processing. The unique functionality of DDX17 within cellular biochemistry makes it an interesting target for specific chemical activators. These activators are characterized by their ability to interact with DDX17, influencing its helicase activity or its expression levels within cells. The exact mechanism of action of these compounds can vary; some may directly interact with the protein, altering its conformation or stability, while others might influence the transcriptional or translational machinery responsible for the production of DDX17, indirectly affecting its activity or concentration in the cellular environment.
The development of DDX17 Activators encompasses a broad range of chemical structures and properties, reflecting the complexity of targeting a protein involved in RNA metabolism. Researchers in the field of biochemistry and molecular biology synthesize and characterize these compounds, aiming to understand the intricate interactions between small molecules and biological macromolecules like DDX17. The focus is primarily on the binding affinity, specificity, and the molecular consequences of these interactions at the biochemical level. These compounds often serve as tools to dissect the biological role of DDX17, helping to elucidate its functions in RNA processing and its interactions with other cellular components. Furthermore, studying DDX17 Activators contributes to the broader understanding of the DEAD box protein family and RNA metabolism. It's important to note that the exploration of these activators is primarily driven by a fundamental scientific interest in understanding molecular and cellular processes, rather than any specific applications outside of basic research.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid, a metabolite of Vitamin A, is involved in cell differentiation and growth. It may influence DDX17 expression as part of the cellular differentiation process. | ||||||
β-Estradiol | 50-28-2 | sc-204431 sc-204431A | 500 mg 5 g | $63.00 $182.00 | 8 | |
β-Estradiol, a form of estrogen, plays a role in regulating gene expression. It may affect DDX17 expression as part of its broader impact on RNA processing mechanisms. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone, a synthetic adrenal corticosteroid, is known to modulate gene expression. Its role in inducing DDX17 expression could be linked to its regulatory effects on RNA synthesis. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Doxorubicin is known to intercalate DNA. Its potential to induce DDX17 expression may be related to cellular responses to DNA damage. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Fluorouracil, a pyrimidine analog, is involved in nucleotide metabolism disruption. This disruption might lead to altered DDX17 expression as part of the cellular stress response. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Tamoxifen, a selective estrogen receptor modulator, influences gene transcription. Its role in DDX17 expression could be linked to estrogen receptor-mediated transcriptional regulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an immunosuppressant, inhibits mTOR signaling. This inhibition may impact DDX17 expression through pathways related to cell growth and proliferation. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride, commonly used in psychiatric treatment, affects signaling pathways. These pathways might influence DDX17 expression through alterations in gene regulation. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic acid, a fatty acid with anticonvulsant properties, is known to affect chromatin remodeling. This effect could lead to changes in DDX17 expression through epigenetic modifications. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol, a natural phenol found in plants, influences various signaling pathways. Its role in inducing DDX17 expression may be related to its impact on cellular stress responses. | ||||||